N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer

被引：0
|
作者：
Haluska, P.
Reinholz, M. M.
Dueck, A. C.
Linden, H. M.
Lingle, W. L.
Bernath, A. M.
Arbushites, M. C.
Youssoufian, H.
Chen, H. X.
Perez, E. A.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin Arizona, Scottsdale, AZ USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Geisinger Hlth Syst, Danville, PA USA
[5] GlaxoSmithKline, Collegeville, PA USA
[6] ImClone Syst, Branchburg, NJ USA
[7] NCI, Canc Therapy Evaluat Program, Rockville, MD USA
[8] Mayo Clin Florida, Jacksonville, FL 32224 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS129
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Hu, Xichun
    Zhang, Qingyuan
    Wang, Leiping
    Zhang, Jian
    Ouyang, Quchang
    Wang, Xiaojia
    Li, Wei
    Xie, Weimin
    Tong, Zhongsheng
    Wang, Shusen
    Xu, Faliang
    Sun, Tao
    Liu, Wei
    Chen, Zhendong
    Wu, Jinsheng
    Wang, Ying
    Wang, Haixia
    Yan, Min
    Wang, Xinshuai
    Wang, Jingfen
    Cao, Feilin
    Du, Yingying
    Zhang, Yongqiang
    Chen, Lilin
    Lu, Ping
    Sun, Sanyuan
    Zhang, Ruiwen
    Zang, Aimin
    Nie, Xiuqing
    Lei, Yuan
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [22] Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
    Xu, Binghe
    Yan, Min
    Ma, Fei
    Hu, Xichun
    Feng, Jifeng
    Ouyang, Quchang
    Tong, Zhongsheng
    Li, Huiping
    Zhang, Qingyuan
    Sun, Tao
    Wang, Xian
    Yin, Yongmei
    Cheng, Ying
    Li, Wei
    Gu, Yuanting
    Chen, Qianjun
    Liu, Jinping
    Cheng, Jing
    Geng, Cuizhi
    Qin, Shukui
    Wang, Shusen
    Lu, Jinsong
    Shen, Kunwei
    Liu, Qiang
    Wang, Xiaojia
    Wang, Hong
    Luo, Ting
    Yang, Jin
    Wu, Yudong
    Yu, Zhiyong
    Zhu, Xiaoyu
    Chen, Chunxia
    Zou, Jianjun
    LANCET ONCOLOGY, 2021, 22 (03): : 351 - 360
  • [23] A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP
    Takano, Toshimi
    Tsurutani, Junji
    Takahashi, Masato
    Yamanaka, Takeharu
    Sakai, Kazuko
    Ito, Yoshinori
    Fukuoka, Junya
    Kimura, Hideharu
    Kawabata, Hidetaka
    Tamura, Kenji
    Matsumoto, Koji
    Aogi, Kenjiro
    Sato, Kazuhiko
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    Saeki, Toshiaki
    BREAST, 2018, 40 : 67 - 75
  • [24] Lapatinib-plus-Pegylated Liposomal Doxorubicin in Advanced HER2-positive Breast Cancer Following Trastuzumab. A Phase II Trial
    Pircher, Magdalena
    Mlineritsch, Brigitte
    Fridrik, Michael A.
    Dittrich, Christian
    Lang, Alois
    Petru, Edgar
    Weltermann, Ansgar
    Thaler, Josef
    Hufnagl, Clemens
    Gampenrieder, Simon Peter
    Rinnerthaler, Gabriel
    Ressler, Sigrun
    Ulmer, Hanno
    Greil, Richard
    ANTICANCER RESEARCH, 2015, 35 (01) : 517 - 521
  • [25] Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer
    Snyder, Raymond D.
    Boyle, Frances M.
    Chan, Arlene
    Craft, Paul S.
    De Boer, Richard
    Mainwaring, Paul N.
    McCarthy, Nicole J.
    Wilcken, Nicholas R.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (01) : 4 - 16
  • [26] Lapatinib plus capecitabine in highly pretreated HER2-positive metastatic breast cancer: A single-institution experience
    Crivellari, D.
    Spazzapan, S.
    Magri, M.
    Frustaci, S.
    Talamini, R.
    Lombardi, D.
    Torrisi, E.
    Scalone, S.
    Miolo, G.
    Veronesi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Immunohistochemical Features Associated with Sensitivity to Lapatinib-plus-Capecitabine and Resistance to Trastuzumab in HER2-positive Breast Cancer
    Cha, Yongjun
    Han, Sae-Won
    Seol, Hyesil
    Oh, Do-Youn
    Im, Seock-Ah
    Bang, Yung-Jue
    Park, In Ae
    Han, Wonshik
    Noh, Dong-Young
    Kim, Tae-You
    ANTICANCER RESEARCH, 2014, 34 (08) : 4275 - 4280
  • [28] Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients
    Dogan, Izzet
    Yildiz, Anil
    Ahmed, Melin Aydan
    Vatansever, Sezai
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024, 15 (03) : 489 - 494
  • [29] Phase II Evaluation of a Novel Capecitabine Schedule in Combination with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab
    Gajria, D.
    Theodoulou, M.
    Feigin, K.
    Patil, S.
    Geneus, S.
    Drullinsky, P.
    D'Andrea, G.
    Lake, D.
    Norton, L.
    Hudis, C.
    Traina, T. A.
    CANCER RESEARCH, 2009, 69 (24) : 803S - 803S
  • [30] Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer
    O'Shaughnessy, Joyce
    Glidden, Andrea
    Locke, Tracy
    Scales, Amy
    CANCER RESEARCH, 2024, 84 (09)
12345